Volume : 13, Issue : 06, June – 2026

Title:

METHOD DEVELOPMENT AND VALIDATION OF RITONAVIR IN PHARMACEUTICAL DOSAGE FORM BY UV VISIBLE SPECTROPHOTOMETRIC METHOD

Authors :

Mrs.K. Srivani *, K.Sravani, A. Rajeshwar Reddy, P. Harshitha, Jomit Thomas, Dr.T. Mangilal

Abstract :

Ritonavir is a protease inhibitor and antiretroviral drug widely used in combination therapy for the treatment of HIV/AIDS and other viral infections. The present study aimed to develop and validate a simple, rapid, accurate, and economical UV spectrophotometric method for the estimation of Ritonavir in bulk drug form. Ritonavir was dissolved in methanol and suitably diluted with distilled water to obtain the required concentrations. Methanol was used as the blank during analysis. For wavelength selection, a 10 µg/mL Ritonavir solution was scanned, and the maximum absorbance (λmax) was observed at 240 nm. The developed method obeyed Beer–Lambert’s law over a concentration range of 5–100 µg/mL. Method validation was performed according to pharmaceutical regulatory guidelines, evaluating parameters such as linearity, accuracy, precision, sensitivity, limit of detection (LOD), and limit of quantification (LOQ). The calibration curve showed good linearity with a regression coefficient (R²) of 0.9613. Accuracy was assessed through recovery studies, with percentage recoveries ranging from 98.7% to 99.8%. Precision studies demonstrated satisfactory reproducibility, with %RSD values less than 2%. The method exhibited good sensitivity, with LOD and LOQ values of 0.314 µg/mL and 0.952 µg/mL, respectively.Residual plot analysis indicated a slight increase in deviations at concentrations above 80 µg/mL, which may be attributed to minor departures from Beer–Lambert’s law and detector saturation at higher absorbance levels. Overall, the validation results confirmed that the developed UV spectrophotometric method is accurate, precise, sensitive, and cost-effective for the routine estimation of Ritonavir in bulk drug samples. Therefore, the method can be successfully employed in quality control laboratories for regular analysis of Ritonavir.
Key Words: Ritonavir, HIV/AIDS, UV spectrophotometric method,Beer–Lambert’s law over a concentration range of 5–100 µg/mL. Method validation was performed according to pharmaceutical regulatory guidelines,and limit of quantification (LOQ).

Cite This Article:

Please cite this article in press K. Srivani et al., Method Development And Validation Of Ritonavir In Pharmaceutical Dosage Form By Uv Visible Spectrophotometric Method, Indo Am. J. P. Sci, 2026; 13(06).

REFERENCES:

1. Bracher, F., et al. (2018). Pharmacokinetic enhancers (boosters)—Escort for drugs against degrading enzymes and beyond. Scientia Pharmaceutica, 86, E43.
2.Chettupalli, A. K., Bukke, S. P. N., Rahaman, S. A., Unnisa, A., Adepu, M., Kavitha, M., & Onohuean, H. (2025). Ritonavir-loaded solid lipid nanoparticles for oral drug delivery and bioavailability enhancement. Discover Applied Sciences, 7(1), 58.
3. Chiranjeevi, K., et al. (2011). Development and validation of UV-Visible spectrophotometric method for estimation of ritonavir in bulk and formulation. International Journal of ChemTech Research, 3(1).
4. De Clercq, E. (2000). Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Reviews in Medical Virology, 10, 255–277.
5. Duraisamy, N., Gopal, N., Mahendiran, A., Rajamani, R., Sundramoorthy, P., Muthuvel, M., & Arthanari, S. (2023). An updated assessment of ritonavir: A protease inhibitor. International Journal of Pharmaceutical Research, 15(4).
6. European Medicines Agency. (1995). Note for guidance on validation of analytical procedures: Text and methodology, 1–15.
7. ICH Harmonized Tripartite Guideline. (1994). Validation of analytical procedures: Text and methodology Q2 (R1).
8. Indian Pharmacopoeia. (2007). Indian Pharmacopoeia (Vol. III, p. 1058).
9.Jitta, S. R., Bhaskaran, N. A., Salwa, & Kumar, L. (2022). Anti-oxidant containing nanostructured lipid carriers of ritonavir: Development, optimization, and in vitro and in vivo evaluations. AAPS PharmSciTech, 23(4), 88.
10.Kempf, D. J., Marsh, K. C., et al. (1995). ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proceedings of the National Academy of Sciences of the United States of America, 92, 2484–2488.
11.Kharasch, E. D., Walker, A., Whittington, D., & Hoffer, C. (2008). Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clinical Pharmacology & Therapeutics, 84, 506–512.
12.Loos, N. H. C., & Schinkel, A. H. (2022). The mechanism-based inactivation of CYP3A4 by ritonavir: What mechanism? International Journal of Molecular Sciences, 23, 9866.
13. Norvir® (ritonavir). (2022). Full prescribing information. North Chicago, IL, USA: AbbVie Inc.
14. Patel, D., Patel, H., & Chaudhary, H. (2021). Formulation development and characterization of darunavir and ritonavir sustained release tablets using Quality by Design approach. Journal of Pharmaceutical Research International, 33(53B), 159–172.
15. Peerzade, M. Y., et al. (2019). Development and validation of UV-Visible spectrophotometric method for estimation of ritonavir in bulk and formulation. Pharma Innovation Journal, 8, 30–34.
16.Ravi Shankar, P., et al. (2024). Ritonavir: 25 years’ experience of concomitant medication management. Infectious Diseases and Therapy, 13, 1005–1017.
17.Ritonavir – C₃₇H₄₈N₆O₅S₂. PubChem.
18. Ritonavir chemical structure. DrugBank.
19.Shitara, Y., Takeuchi, K., & Horie, T. (2013). Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. Journal of Pharmaceutical Sciences, 102, 3427–3435.
20.United States Pharmacopoeia, National Formulary. (2007). United States Pharmacopoeia (Vol. 25, p. 2143).
21.Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138, 103–141.
22. Gollapalli et al.; J. Adv. Med. Pharm. Sci., vol. 27, no. 12, pp. 58-68, 2025; Article no. JAMPS.142213